Basic Information
PHAXIAM is a biopharmaceutical company developing innovative treatments for drug-resistant bacterial infections, which are responsible for many severe infections. The company is pioneering a novel phage-based approach, utilizing bacteriophages, which are natural bacteria-killing viruses. PHAXIAM is advancing combinations of phages targeting the three most drug-resistant and dangerous bacteria: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.